Dose Escalation of Bevacizumab With Ambulatory Blood Pressure Monitoring in Patients With Advanced Non-squamous NSCLC

Advanced Non-squamous Non-Small Cell Lung Cancer Clinical Trial

— AVF4759  

Official title:

A Randomized, Open-Label, Dose Escalation Study of Bevacizumab With Ambulatory Blood Pressure Monitoring in Previously Untreated Patients With Advanced Non-squamous Non-Small Cell Lung Cancer

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01063283
• Other study ID #: 10-014-B
• Status: Completed
• Phase: N/A
• Start date: March 2010
• Est. completion date: June 2016

Study information

• Verified date: October 2019
• Source: University of Chicago
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to see if higher dose of bevacizumab can be taken safely by some patients and if changes in the dose of bevacizumab have any effect on blood pressure.

Description:

Carboplatin and pemetrexed are FDA approved chemotherapy agents for patients with advanced non squamous non small cell lung cancer. Bevacizumab is also FDA approved in lung cancer , and the combination of all three drugs is promising. The doctors directing this research want to learn how to better personalize drug dosing of bevacizumab by identifying people who could safely take a higher dose of the drug.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 20
• Est. completion date: June 2016
• Est. primary completion date: June 2016
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 89 Years

Eligibility

Inclusion Criteria:

• Patients must have histologically or cytologically confirmed, newly diagnosed Stage IIIB, stage IV, or recurrent non-squamous NSCLC for which they have not received chemotherapy.

• Patients must have completed radiation therapy 2 weeks prior to enrollment. Patients may have received adjuvant therapy, provided the regimen included no more than one of the study agents.

• Patients must have measurable disease, defined as at least one lesion that can be accurately measured in at least one dimension.

• Age >18 years. •Life expectancy of greater than 4 months.

• ECOG performance status of 0 or 1

• Patients must have normal organ and marrow function

• Patients on anticoagulation are allowed.

• Women of child-bearing potential and men must agree to use adequate contraception prior to study entry and for the duration of study participation.

• Ability to understand and the willingness to sign a written informed consent document.

Exclusion Criteria:

Disease-Specific

• Patients who have had received prior chemotherapy (in the setting of recurrent disease, other than their original adjuvant therapy)

• Patients may not be receiving any other investigational agents.

• Patients with histologic evidence of predominantly squamous lung cell cancer

• General Medical Exclusions

• Inability to comply with study and/or follow-up procedures

• Malignancy other than superficial basal cell and superficial squamous of the skin or carcinoma in situ of the cervix within last five years

Bevacizumab-Specific Exclusions

• Inadequately controlled hypertension

• Prior history of hypertensive crisis or hypertensive encephalopathy

• New York Heart Association Grade II or greater congestive heart failure

• History of myocardial infarction or unstable angina within 6 months prior to Day 1

• History of stroke or transient ischemic attack within 6 months prior to Day 1

• Known CNS disease, except for treated brain metastasis.

• Significant vascular disease within 6 months prior to Day 1

• History of hemoptysis within 1 month prior to Day 1

• Evidence of bleeding diathesis or significant coagulopathy

• Major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to Day 1 or anticipation of need for major surgical procedure during the course of the study

• Core biopsy or other minor surgical procedure, excluding placement of a vascular access device, within 7 days prior to Day 1

• History of diverticulitis, abdominal fistula or gastrointestinal perforation within 6 months prior to Day 1

• Serious, non-healing wound, active ulcer, or untreated bone fracture

• Proteinuria as demonstrated by a UPC ratio 1.0 at screening

• Known hypersensitivity to any component of bevacizumab

• Pregnancy (positive pregnancy test) or lactation.

• Mixed tumors will be categorized by the predominant cell type unless small cell elements are present.

• Uncontrolled intercurrent illness including, ongoing or active infection or psychiatric illness/social situations that would limit compliance with study requirements.

• Any unstable condition that in the opinion of the investigator is likely to interfere with collection of accurate blood pressure measurement data .

• HIV-positive patients on combination antiretroviral therapy.

Related Conditions & MeSH terms

• Advanced Non-squamous Non-Small Cell Lung Cancer
• Carcinoma, Non-Small-Cell Lung
• Lung Neoplasms

Intervention

Drug:
• Pemetrexed
Pemetrexed 500 mg/m^2 intravenously over 10 minutes
• Carboplatin
Carboplatin at a dose calculated to produce an area under the concentration-time curve of 6 mg/ml•min intravenously over 30 minutes
• Bevacizumab 7.5 mg/kg
Bevacizumab at 7.5 mg/kg intravenously over 90 minutes
• Bevacizumab 15 mg/kg
Bevacizumab at 15 mg/kg intravenously over 90 minutes

Locations

Country	Name	City	State
United States	The University of Chicago Medical Center	Chicago	Illinois
United States	North Shore University Health System	Evanston	Illinois
United States	Ingalls Memorial Hospital	Harvey	Illinois

Sponsors (2)

Lead Sponsor	Collaborator
University of Chicago	Genentech, Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change in 24 Hour Diastolic Blood Pressure (DBP)	The change for each patient was calculated as mean 24 hour DBP during cycle 2 - mean 24 hour DBP during cycle 1	2 cycles
Secondary	Response Rate	Percentage of patients with a complete or partial response. Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), >=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR.	2 years
Secondary	Change in Tumor Size From Baseline		2 years
Secondary	Progression Free Survival	Time to progression or death from any cause, whichever comes first	2 years